Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Original Article

CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway

Authors: Xu Hou, Ying Zhang, Haiquan Qiao

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

CCL18 is a member of CCL chemokines and is frequently overexpressed in cancer. Elevated CCL18 expression has been reported to be associated with poor prognosis of gastric cancer. However, the molecular mechanisms of CCL18 in gastric cancer cells remain elusive. In our study, we found that CCL18 was highly expressed in different gastric cancer cells. CCL18 stimulation dose-dependently enhanced the invasion and migration of MGC-803 cells. Knockdown of endogenous CCL18 inhibited the invasion and migration of MGC-803 cells, whereas overexpression of CCL18 promoted the invasion and migration of MKN28 cells. We further found that CCL18 increased the expressions of MMP-3 and Slug and decreased the expression of E-cadherin in MGC-803 cells. In addition, CCL18 time-dependently induced activation of ERK1/2, IκBα, and NF-κB. These effects of CCL18 were prevented by ERK1/2 selective inhibitor U0126 as well as NF-κB selective inhibitor BAY117082. Taken together, our findings establish a signaling role for CCL18 in gastric cancer cells and identify that the CCL18/ERK1/2/NF-κB signaling pathway is essential for tumor invasiveness in gastric cancer cells. Thus, our data may provide knowledge for using CCL18 as a novel target for effective diagnosis and treatment of gastric cancer.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2010;27:1246–53.CrossRefPubMed
5.
Xu Y, Zhang L, Sun SK, Zhang X. CC chemokine ligand 18 and IGF-binding protein 6 as potential serum biomarkers for prostate cancer. Tohoku J Exp Med. 2014;233:25–31.CrossRefPubMed
6.
Plones T, Krohn A, Burger M, Veelken H, Passlick B, Muller-Quernheim J, et al. Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. PLoS One. 2012;7, e41746.CrossRefPubMedPubMedCentral
7.
Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ, et al. CC chemokine ligand 18 correlates with malignant progression of prostate cancer. Biomed Res Int. 2014;2014:230183.PubMedPubMedCentral
8.
Miyagaki T, Sugaya M, Suga H, Ohmatsu H, Fujita H, Asano Y, et al. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis. J Eur Acad Dermatol Venereol. 2013;27:e60–7.CrossRefPubMed
9.
Narita D, Seclaman E, Ursoniu S, Ilina R, Cireap N, Anghel A. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Romanian J Morphol Embryol. 2011;52:1261–7.
10.
Yuan R, Chen Y, He X, Wu X, Ke J, Zou Y, et al. CCL18 as an independent favorable prognostic biomarker in patients with colorectal cancer. J Surg Res. 2013;183:163–9.CrossRefPubMed
11.
12.
Verma S, Kesh K, Ganguly N, Jana S, Swarnakar S. Matrix metalloproteinases and gastrointestinal cancers: impacts of dietary antioxidants. World J Biol Chem. 2014;5:355–76.CrossRefPubMedPubMedCentral
13.
Peng Z, Wang CX, Fang EH, Wang GB, Tong Q. Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol. 2014;20:5403–10.CrossRefPubMedPubMedCentral
14.
Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, et al. Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urol. 2013;13:42.CrossRefPubMedPubMedCentral
15.
Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers. 2011;26:262–73.PubMed
16.
Sakane R, Tsubamoto H, Sakata K, Inoue K, Ogino M, Shibahara H, et al. Expression of chemokine ligand 18 in stage IA low-grade endometrial cancer. Anticancer Res. 2014;34:5331–6.PubMed
17.
Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther. 2014;141:160–71.CrossRefPubMed
18.
19.
20.
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278:16–27.CrossRefPubMed
21.
Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP. Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol. 2007;171:428–37.CrossRefPubMedPubMedCentral
22.
Liu HQ, Song S, Wang JH, Zhang SL. Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance. Oncol Lett. 2011;2:1319–22.PubMedPubMedCentral
23.
Gencer S, Cebeci A, Irmak-Yazicioglu MB. Silencing of the MMP-3 gene by siRNA transfection in gastric cancer AGS cells. J Gastrointestin Liver Dis. 2011;20:19–26.PubMed
24.
25.
Ploenes T, Scholtes B, Krohn A, Burger M, Passlick B, Muller-Quernheim J, et al. CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential. PLoS One. 2013;8, e53068.CrossRefPubMedPubMedCentral
Metadata
Title
CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway
Authors
Xu Hou
Ying Zhang
Haiquan Qiao
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3825-0

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Review

Cancer stem cells in human digestive tract malignancies

Original Article

Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation

Original Article

Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia

Original Article

Involvement of nuclear protein C23 in activation of EGFR signaling in cervical cancer

Original Article

Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy

Original Article

Targeting polyamine biosynthetic pathway through RNAi causes the abrogation of MCF 7 breast cancer cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits